Weakened and brittle bones contribute to an estimated 25,000 fractures that occur each day around the world. Bones tend to become more fragile with age and research shows that more than 90% of hip fractures are the result of a fall.
It is possible that aspirin may reduce low-grade inflammation associated with age-related bone fragility. However, previous studies have been inconsistent about the effect of aspirin on bones.
The ASPREE-Fracture sub-study will determine whether daily low-dose aspirin reduces the risk of older Australians having a bone fracture. It will also investigate whether aspirin reduces the risk of having a fall that results in hospital attendance.
The ASPREE-Fracture sub-study is the first double-blind, randomised, placebo-controlled trial of aspirin and fracture risk in healthy older people.
What does participation involve?
This study collects relevant information entirely through medical records. If a participant has sustained a fracture, or attended a hospital or emergency department because of a fall since enrolling in the trial, we will follow up with their health provider to collect information about the fracture and/or treatment.
Results will be collated in 2017 to determine whether a daily low dose of aspirin can prevent or reduce the number of fractures and fall-related hospital presentations experienced by older people.
How to find out more about the ASPREE-FRACTURE study:
- Ring 1800 728 745 (toll free from a landline)
Collaborators:
- Monash University
- University of Melbourne
- Western Health
- Austin Health
- The Mayo Clinic, USA
- University of Sydney
- Deakin University
- Co-investigating GPs
Funding:
- The Australian National Health and Medical Research Council (NHMRC)